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Background:Despite the recent development of endovascular therapy (EVT), a high incidence of restenosis remains as an
unsolved issue in patients presenting with femoropopliteal lesions. We investigated whether cilostazol reduces restenosis
after successful EVT for de novo femoropopliteal lesions.
Methods:This study was designed as a prospective, randomized, open-label, blinded end point study in a single institution.
Between March 2004 and June 2005, we randomized 127 patients who were successfully treated with EVT for de novo
femoropopliteal lesions to receive cilostazol (200 mg/d, n 63) or ticlopidine (200 mg/d, n 64) in addition to aspirin
(100 mg/d). Antiplatelet medications were started at least 1 week before EVT and were continued until the end of
follow-up. Patency was defined by duplex ultrasound imaging with peak systolic velocity ratio >2.4.
Results: There were no significant differences in the patients and lesion characteristics. Sixteen patients dropped out of the
study protocol, six of whom were withdrawn due to adverse drug effects (cilostazol, n  5; ticlopidine, n  1; P  .09).
Ten patients died (cilostazol, n 4; ticlopidine, n 6; P .53) during the follow-up period. Patency rates at 12, 24, and
36 months were 87%, 82%, and 73% in the cilostazol group and 65%, 60%, and 51% in ticlopidine group by
intention-to-treat analysis (P .013) and were 87%, 82%, and 73% in the cilostazol group and 64%, 57%, and 48% in the
ticlopidine group (P  .0088) by as-treated analysis. Freedom from target lesion revascularization and all adverse events
(restenosis, amputation, and death) was significantly higher in cilostazol group than in ticlopidine group (P  .036, P 
.031). No acute, subacute, or chronic thrombotic occlusion was encountered, and bleeding complication rates were
similar between the two groups.
Conclusions: Cilostazol significantly reduces restenosis after EVT in femoropopliteal lesions. (J Vasc Surg 2008;48:144-9.)The strategy of revascularization for peripheral artery
disease (PAD) has been shifting from surgical bypass ther-
apy toward endovascular therapy (EVT) in recent years.1 In
the femoropopliteal (FP) lesions, however, whether revas-
cularization is superior in terms of vessel patency and
operative mortality remains controversial. Bypass graft sur-
gery was recommended for most FP lesions rather than
EVT in TransAtlantic Inter-Society Consensus (TASC) in
2000 partly because of the high restenosis rate in EVT.2
Despite better outcomes, however, a high incidence of
postoperative complications remains a problem in FP lesion
surgery.3
New nitinol stents have recently been introduced as the
first-line treatment, resulting in an improved long-term
patency.4-7 Primary self-expanding nitinol stent implanta-
tion in FP lesions has been shown to be superior to con-
ventional balloon angioplasty in intermediate terms.8,9
Thus, EVT has increasingly become an attractive alternative
to bypass graft surgery in FP lesions.
On the other hand, neointimal hyperplasia is a major
mechanism for restenosis after EVT. Several adjunctive
therapies have been proposed to reduce the high restenosis
rate in FP lesions after EVT. Intravascular brachytherapy
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144demonstrated encouraging results for the prevention of
restenosis in middle-term results, but long-term results
were far from satisfactory.10-12 Sirolimus-eluting nitinol
stents for the superficial femoral artery (SFA) showed a
trend toward a reduced late loss compared with uncoated
stents after 6months but demonstrated no beneficial effects
on angiographic restenosis at the 2-year follow-up.13-15
Hence, the reduction of angiographic restenosis and target
lesion revascularization (TLR) after EVT in FP lesions
remains as a challenge.
We have previously observed in a retrospective study
that orally administered cilostazol reduced the frequency of
TLR after successful EVT for de novo FP lesions.16 Never-
theless, the previous study was retrospective, and whether
cilostazol reduces restenosis after EVT for FP lesions re-
mains unknown. Thus, the purpose of this study was to
prospectively investigate whether cilostazol reduces reste-
nosis after successful EVT for de novo FP lesions.
METHODS
Study design. This study was designed as a prospec-
tive, randomized, open-label, blinded, end point study in a
single institution. The study consecutively enrolled 127
patients who were admitted to the Cardiovascular Division
of Kansai Rosai Hospital from March 2004 to June 2005
for the treatment of PAD and underwent EVT for symp-
tomatic de novo FP lesions. Indications were claudication in
95 (75%) and limb-threatening ischemia in 32 (25%). The
protocolwas approved by the Institutional EthicsCommittee,
and all patients providedwritten informed consent. This study
is registered with the University Hospital Medical Informa-
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was acceptable to the International Committee of Medical
Journal Editors, (No UMIN000001036).
Before EVT commenced for FP lesions, 63 patients
were randomized to receive oral cilostazol (200mg/d) and
64 to receive ticlopidine (200 mg/d); both groups also
received aspirin (100 mg/d). Randomization was per-
formed with the use of computer-generated random digits,
and the assignments were placed in sealed envelopes. The
antiplatelet medication was started at least 1 week before
EVT and continued until the end of follow-up.
Patients met the following anatomic inclusion criteria:
de novo FP lesions of 50% diameter stenosis, occlusion
without inflow lesions (the aortoiliac or common femoral
artery), and with outflow lesions of the below the knee
arteries of more than one vessel runoff as evaluated by
angiography. Patients also met clinical inclusion criteria of
symptomatic PAD with claudication (Fontaine 2), intrac-
table rest pain (Fontaine 3), and nonhealing ulcer (Fon-
taine 4) due to FP lesions. The exclusion criteria were acute
onset critical limb ischemia, previous bypass surgery or
angioplasty for the FP lesions, presence of untreated pelvic
lesions, and known intolerance to the medication or con-
trast agents.
Study end points. The primary end point of this study
was patency in treated segments. The secondary end points
were TLR and all events, including restenosis, amputation,
and death from any causes. Two independent observers
blinded to the medication evaluated all follow-up data.
Intervention procedure. EVT for FP lesions was per-
formed either by antegrade approach or crossover through
the bifurcation approach using a 6F or 7F sheath. A
0.035-or 0.014-inch wire was inserted into the lesion.
Unfractionated heparin (5000 U) was injected into the
artery. The lesion was expanded using an optimal balloon
for 60 seconds. A self-expanding stent was implanted in
accordance with the American College of Cardiology/
American Heart Association guidelines in patients present-
ing with a residual pressure gradient10 mmHg, residual
stenosis 30%, or flow-limiting dissection after balloon
dilatation. A nitinol stent (Luminexx, C.R. Bard, Murray
Hill, NJ) or cobalt metallic stent (Wallstent, Boston Scien-
tific, Natick, Mass) with the diameter 1 mm larger than the
reference diameter was used. Stents of 6 mm in diameter
were used in most cases. Selection of stents was dependent
on the era of EVT: The Luminexx stent was used from
March 2004 to October 2004, and the Wallstent was used
from November 2004 to June 2005.
Assessment of primary and secondary end points.
Clinical follow-up after EVT was performed at 1, 3, and 6
to 12 months, and every 3 months afterwards and included
physical examinations, ankle-brachial index measurement,
and duplex ultrasound (DUS) imaging. Patency was de-
fined as peak systolic velocity ratio 2.4 by DUS.17 All
adverse events, including restenosis, TLR, amputation, and
deaths from any cause were evaluated.
Statistical analysis. Statistical analysis was performed
using Dr SPSS software (SPSS Inc, Chicago, Ill). Data areshown as mean  standard deviation. The unpaired t test
was used to compare the continuous variables between the
groups, and the 2 test was used to compare ratios between
the groups. The statistical significance was level set at P 
.05. Patency, freedom from TLR, and freedom from all
adverse events were determined with Kaplan-Meier survival
analysis and compared with log-rank testing.
RESULTS
Patients, lesion characteristics, and interventional
procedures. The demographic data of the patients and the
lower limb lesions are listed by treatment groups in Table I.
Atherosclerotic risk factors such as hypertension, hypercho-
lesterolemia, diabetes mellitus, and current smoking did
not significantly differ between the groups. Patients in both
groups had similar Fontaine classifications. There were no
significant differences in the lesion characteristics evaluated
by TASC classification (Table II). Interventional proce-
dures such as the types of stent used, frequency of stenting,
or incidence of stent fracture at follow-up were similar be-
tween the groups (Table III). Bleeding complication rates
were similar between the two groups (Table IV).
Drop-out patients. Follow-up data were obtained
from all 127 patients. Sixteen patients dropped out of the
study protocol, six of whom withdrew because of adverse
drug effects (P  .09). Five patients in cilostazol group
withdrew because of palpitation (n 3), leg edema (n 1),
and headache (n  1); and one patient in the ticlopidine
group withdrew because of an abnormal result on a liver
function test. All patients who stopped taking cilostazol
or ticlopidine during follow-up received beraprost so-
Table I. Patient and lower limb characteristics
Characteristic Treatment group  aspirin
PNo., No. (%), or mean  SD Cilostazol Ticlopidine
Patients in group 63 64
Sex .51
Male 19 16
Female 44 48
Age, years 70  9 70  8 .94
Hypertension 59 (94) 59 (92) .74
Hypercholesterolemia 33 (52) 34 (53) .93
LDL cholesterol, mg/dL 114  27 119  39 .37
Statin use 19 (30) 22 (34) .29
Diabetes mellitus 46 (73) 46 (72) .88
Current smoking 39 (62) 37 (58) .63
Renal insufficiencya 16 (25) 19 (30) .58
Coronary artery disease 38 (60) 42 (66) .53
Symptomatic cerebral
infarction
12 (19) 11 (17) .78
Fontaine classification .61
II 45 50
III 5 5
IV 13 9
Preprocedure ABI 0.60  0.23 0.57  0.22 .43
ABI, Ankle-brachial index; LDL, low-density lipoprotein; SD, standard
deviation.
aDefined as serum creatinine 2 mg/dL.dium (40 g/d).
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the ticlopidine group (P  .53). The causes of death were
acute myocardial infarction in 2, sudden death in 1, and
renal failure in 1 in cilostazol group; and acute myocardial
infarction in 3, sudden death in 2, and renal failure in 1 in
ticlopidine group.
Primary end point. Follow-up with DUS was com-
pleted in the 117 surviving patients. Five patients required
leg amputation, four in the cilostazol group and one in the
Table II. Lesion characteristic before and after
intervention procedure
Characteristic
Treatment group
aspirin
PNo., No. (%), or mean SD Cilostazol Ticlopidine
Patients 63 64
TASC classification .50
A 7 5
B 6 9
C 21 27
D 29 23
Superficial femoral artery 59 56 .24
Popliteal artery 4 8
Lesion length, mm 141  102 134  97 .71
Pretreatment variables
Minimum lumen diameter, mm 1.4  1.2 1.6  1.1 .23
Diameter stenosis, % 72  20 67  19 .31
Reference vessel diameter, mm 4.6  1.5 5.1  1.4 .12
Chronic total occlusion 32 (51) 27 (43) .37
Lesion calcification 27 (43) 34 (53) .25
BTK runoff .11
0 6 3
1 26 17
2 19 22
3 12 22
Post-treatment variables
Minimum lumen diameter, mm 5.2  1.2 5.3  1.0 .41
Diameter stenosis, % 13  10 12  9 .61
BTK, Below the knee; TASC, TransAtlantic Inter-Society Consensus.
Table III. Interventional procedure
Procedure
Treatment group  aspirin
P
Cilostazol
(n  63)
Ticlopidine
(n  64)
No. of stents .33
0 8 10
1 33 38
2 14 14
3 6 2
4 2 0
Stent frequency, No. % 56 (89) 54 (84) .46
Stent implantation .74
Luminexx,a No. % 30 (48) 28 (44)
Wallstent,b No. % 26 (41) 26 (40)
Stent fracture at
follow-up, No (%) 11/56 (20) 9/54 (17) .75
aC. R. Bard, Murray Hill, NJ.
bBoston Scientific, Natick, Mass.ticlopidine group. Two of the cilostazol patients had rest-enotic lesions, and femorotibial bypass was performed in
one patient who eventually underwent below knee amputa-
tion due to the delayed healing. The other patients underwent
primary amputation due to uncontrollable infection.
The patency rate was significantly higher in the cilosta-
zol group than in the ticlopidine group (Fig 1, A by
intention-to-treat analysis, P .013; Fig 1, B by as-treated
analysis, P  .0088). The patency rates for the different
types of stent used are shown in Fig 2. Patency of the nitinol
stents in each group tended to be higher than cobalt stents.
Secondary end point. Freedom from TLR compared
between the cilostazol and ticlopidine groups is shown in Fig
3. TLR was less frequent in the cilostazol group (P  .036).
Adverse events including death, amputation, and restenosis
were significantly lower in patients treatedwith cilostazol than
in those treated with ticlopidine (P .031, Fig 4).
DISCUSSION
In our study, the intention-to-treat analysis and the
as-treated analysis both showed patency was significantly
higher in patients treated with cilostazol than with ticlopi-
dine. Freedom from adverse events, including death, am-
putation, and restenosis was also significantly higher in
cilostazol group.
Restenosis subsequent to revascularization has been a
major drawback of EVT in FP lesions.18,19 TASC 2000 did
not recommend primary stenting because of the poor long-
term patency.2 Restenosis caused by intimal hyperplasia in
stented segments is quite common in the first 3 to 9
months; hence, metallic stents had a limited role to bail out
acute failure in balloon angioplasty.2 Recently, the use of
new nitinol stents has improved the durability of stenting
for the SFA, with only a 5% restenosis rate at 6months.7 For
the TASC A and B lesions defined by TASC II, a recent
randomized trial has demonstrated that primary patency
was significantly higher after a new nitinol stent than after
balloon angioplasty.8,9 Currently, EVT using nitinol stents
has become widely applied for SFA lesions, and TASC II
included much expanded recommendations for EVT (15
cm occlusions) in the FP lesions.20
Nonetheless, long-term patency of the nitinol stent was
poorer than that of bypass surgery using vein grafts. In fact,
Table IV. Thrombotic occlusion and bleeding
complications
Event
Treatment group 
aspirin
P
Cilostazol
(n  63)
Ticlopidine
(n  64)
Thrombotic occlusion,a No. 0 0 .99
Bleeding complication (overall), No. 5 8 .72
Access site 4 6
Cerebral hemorrhage 1 0
Gastric ulcer 0 2
aDefined as acute, subacute, or chronic.EVT was not recognized as an attractive alternative to
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proved efficacious for coronary intervention have been
attempted in SFA lesions, such as drug-eluting stents,13-15
drug-eluting balloons,20 and vascular brachytherapy,10-12
but they have not showed satisfactory results in reducing
restenosis.
Currently, there is no “established” treatment for FP
lesions. Medical treatment after EVT intends to prevent
not only early interventional failure due to thrombotic
Fig 1. Patency after endovascular therapy (primary end point) for
symptomatic de novo femoropopliteal lesions compared between
patients receiving cilostazol (solid circles) and ticlopidine (clear
circles). Patency was evaluated by duplex ultrasonography (peak
systolic velocity ratio 2.4). (A) By intention-to-treat analysis,
patency rates at 12, 24, and 36 months were 87%, 82%, and 73% in
the cilostazol group and 65%, 60%, and 51% in ticlopidine group
(P .013). (B) By as-treated analysis, patency rates at 12, 24, and
36 months were 87%, 82%, and 73% in the cilostazol group and
64%, 57%, and 48% in ticlopidine group (P  .0088).occlusion but also future cardiovascular events.20 Hence,life-long oral antiplatelet therapy, such as acetylsalicylic acid
and clopidogrel, is important for both systemic and local
reasons. Nonetheless, none of the additional medical ther-
apies to EVT have so far prevented restenosis in FP le-
sions.20 Our current study, to our knowledge, was the first
to prospectively study the effects of cilostazol and ticlopi-
dine on restenosis in FP lesions.
Restenosis particularly progresses within the first year in
prospective studies using cobalt metallic stents21 and niti-
Fig 2. Patency for the different types of stent used: nitinol stents
(NI, filled symbol) vs cobalt metallic stents (Co, open symbol) com-
pared between the cilostazol (circles) group and the ticlopidine
(squares) group. Patency of nitinol stents used in the cilostazol
group tended to be the highest among the groups (P  .09).
Fig 3. Freedom from target lesion revascularization (TLR) com-
pared between the cilostazol (circles) group and the ticlopidine
(squares) group (secondary end point). Freedom from TLR at 12,
24, and 36 months was significantly higher in the cilostazol group
than in the ticlopidine group (88%, 82%, and 82% vs 73%, 70%, and
58%; P  .036).nol stents.8,9 Hence, the most essential issue, as with the
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ing the first year after EVT. It should be noted that in our
study, cilostazol reduced the restenosis during the first year,
and continuing the medication maintained the patency.
With the cilostazol treatment, fewer patients had reste-
nosis, similar to the results obtained in the Carotid Revas-
cularization Endarterectomy vs. Stent Trial (CREST).22
Furthermore, earlier studies have indicated that cilostazol
improves symptoms and walking distance in patients with
PAD with intermittent claudication.23 Consequently,
cilostazol is a class 1 drug for patients with PAD according
to the American Heart Association guidelines24 and the
new essential TASC.20
Cilostazol, a phosphodiesterase type 3 inhibitor, in-
creases the concentration of cyclic adenosine monophos-
phate. It has multiple effects, such as inhibition of platelet
activation, vasodilation, antiproliferation of vascular smooth
muscle cells, and improvement of endothelial cell func-
tion.25-29 These effects may lead to the inhibition of neo-
intimal hyperplasia after stent placement in the FP lesions.
These results suggest that cilostazol is feasible as a first-line
oral drug after EVT for FP lesions.
This study was a prospective, randomized, open-label,
blinded end point study, and the lack of a control groupwas
the one of the study limitations. Because of ethical con-
cerns, we could not place a placebo control group in this
study. Dose-response analysis was not done before the
study, although we used a regular clinical dose of either
cilostazol or ticlopidine. A large-scale study should be
warranted based on the results of this study.
CONCLUSION
Cilostazol after endovascular therapy for femoropopli-
teal lesions was more effective in reducing restenosis than
Fig 4. Freedom from all adverse events (secondary end point),
including death, amputation and restenosis was significantly higher
at 12, 24, and 36months in patients treated with cilostazol (circles)
than in those treated with ticlopidine (squares): 77%, 72%, and 60%
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